Intravenous immunoglobulin use in hemolytic disease due to ABO incompatibility to prevent exchange transfusion

Basit Öğe Kaydı
dc.authorid0000-0002-1101-3355en_US
dc.authorid0000-0002-3193-0812en_US
dc.authorid0000-0003-4006-0465en_US
dc.contributor.authorOkulu, Emel
dc.contributor.authorErdeve, Ömer
dc.contributor.authorKılıç, İlknur
dc.contributor.authorOlukman, Özgür
dc.contributor.authorÇalkavur, Şebnem
dc.contributor.authorBüyükkale, Gökhan
dc.contributor.authorErtuğrul, Sabahattin
dc.date.accessioned2024-03-04T13:31:02Z
dc.date.available2024-03-04T13:31:02Z
dc.date.issued2022en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractIntroduction: Intravenous immunoglobulin (IVIG) has been widely used to treat the hemolytic disease of the newborn (HDN). Although it has been shown that IVIG treatment reduces the duration of phototherapy and hospitalization, the use of IVIG in hemolytic disease due to ABO incompatibility has been controversial in recent years. This study aimed to investigate the role of IVIG in the prevention of exchange transfusion in infants with ABO HDN who presented with bilirubin levels at or above the level of exchange transfusion. Materials and Methods: This study evaluated the data of infants with ABO HDN in the Turkish Neonatal Jaundice Online Registry. The infants with ABO HDN who met the total serum bilirubin level inclusion criteria (within 2–3 mg/dL of exchange transfusion or even above exchange transfusion level) were included in the study according to the guidelines from the American Academy of Pediatrics and the Turkish Neonatal Society. All patients were managed according to the unit protocols recommended by these guidelines and received light-emitting diode (LED) phototherapy. Infants who only received LED phototherapy, and who received one dose of IVIG with LED phototherapy were compared. Results: During the study period, 531 term infants were included in the study according to inclusion criteria. There were 408 cases in the phototherapy-only group, and 123 cases in the IVIG group. The demographic findings and the mean bilirubin and reticulocyte levels at admission were similar between the groups (p > 0.05), whereas the mean hemoglobin level was slightly lower in the IVIG group (p = 0.037). The mean age at admission was earlier, the need for exchange transfusion was higher, and the duration of phototherapy was longer in the IVIG group (p < 0.001, p = 0.001, and p < 0.001, respectively). The rate of re-hospitalization and acute bilirubin encephalopathy (ABE) was higher in the IVIG group (p < 0.001 and p = 0.01, respectively). Conclusion: In this study, we determined that one dose of IVIG did not prevent an exchange transfusion nor decrease the duration of phototherapy in infants, who had bilirubin levels near or at exchange transfusion level, with hemolytic disease due to ABO incompatibility.en_US
dc.identifier.citationOkulu, E., Erdeve, Ö., Kılıç, İ., Olukman, Ö., Çalkavur, Ş., Büyükkale, G. ve diğerleri. (2022). Intravenous immunoglobulin use in hemolytic disease due to ABO incompatibility to prevent exchange transfusion. Frontiers in Pediatrics, 10, 1-6.en_US
dc.identifier.doi10.3389/fped.2022.864609
dc.identifier.endpage6en_US
dc.identifier.issn2296-2360
dc.identifier.scopus2-s2.0-85133912076
dc.identifier.scopusqualityQ2
dc.identifier.startpage1en_US
dc.identifier.urihttps://www.frontiersin.org/articles/10.3389/fped.2022.864609/full
dc.identifier.urihttps://hdl.handle.net/11468/13505
dc.identifier.volume10en_US
dc.identifier.wosWOS:000881839300001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorErtuğrul, Sabahattin
dc.language.isoenen_US
dc.publisherFrontiers Media S.A.en_US
dc.relation.ispartofFrontiers in Pediatrics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectABO incompatibilityen_US
dc.subjectExchange transfusionen_US
dc.subjectHemolytic disease of the newbornen_US
dc.subjectIntravenous immunoglobulinen_US
dc.subjectLight-emitting diodeen_US
dc.subjectPhototherapyen_US
dc.titleIntravenous immunoglobulin use in hemolytic disease due to ABO incompatibility to prevent exchange transfusionen_US
dc.titleIntravenous immunoglobulin use in hemolytic disease due to ABO incompatibility to prevent exchange transfusion
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Intravenous Immunoglobulin Use in Hemolytic Disease Due to ABO Incompatibility to Prevent Exchange Transfusion.pdf
Boyut:
481.83 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu